Targets › DECTIN1
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Sep 2027.
Lectin that functions as a pattern recognizing receptor (PRR) specific for beta-1,3-linked and beta-1,6-linked glucans, which constitute cell wall constituents from pathogenic bacteria and fungi. Necessary for the TLR2-mediated inflammatory response and activation of NF-kappa-B: upon beta-glucan binding, recruits SYK via its ITAM motif and promotes a signaling cascade that activates some CARD domain-BCL10-MALT1…. (UniProt, Q9BXN2)
Open in Phaseline: the race on DECTIN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Abramson Cancer Center at Penn Medicine | Odetiglucan Dectin-1 agonist | DECTIN1 | Phase 2 | Colorectal Adenocarcinoma Metastatic in the Liver | Sep 2027 |
| University of Pennsylvania | Odetiglucan Dectin-1 agonist | DECTIN1 | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oct 2027 |
Pancreatic Ductal Adenocarcinoma (1) Colorectal Adenocarcinoma Metastatic in the Liver (1)
mixed (2)
University of Pennsylvania (1) Abramson Cancer Center at Penn Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.